Voya Investment Management LLC decreased its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 6.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 664,017 shares of the medical technology company’s stock after selling 47,753 shares during the period. Voya Investment Management LLC owned approximately 0.05% of Medtronic worth $57,298,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of MDT. BlackRock Inc. increased its position in Medtronic by 0.7% during the second quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock worth $8,919,846,000 after acquiring an additional 838,220 shares during the period. State Street Corp raised its stake in Medtronic by 2.7% in the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after purchasing an additional 1,658,301 shares in the last quarter. Bank of America Corp DE raised its stake in Medtronic by 5.4% in the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after purchasing an additional 1,343,220 shares in the last quarter. First Eagle Investment Management LLC boosted its holdings in Medtronic by 1.2% in the 3rd quarter. First Eagle Investment Management LLC now owns 13,948,408 shares of the medical technology company’s stock valued at $1,203,608,000 after purchasing an additional 164,425 shares during the period. Finally, Amundi boosted its holdings in Medtronic by 36.3% in the 1st quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock valued at $525,986,000 after purchasing an additional 1,616,739 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.
Medtronic Stock Performance
NYSE:MDT opened at $100.76 on Thursday. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The stock’s 50-day simple moving average is $94.26 and its 200 day simple moving average is $88.48. The firm has a market capitalization of $128.89 billion, a PE ratio of 24.82, a price-to-earnings-growth ratio of 2.39 and a beta of 0.56.
Medtronic (NYSE:MDT – Get Free Report) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business’s quarterly revenue was up 13.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, analysts anticipate that Medtronic PLC will post 5.98 EPS for the current fiscal year.
Insider Activity at Medtronic
In other Medtronic news, EVP Michael Marinaro sold 10,420 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the sale, the executive vice president owned 105,916 shares in the company, valued at $10,167,936. This trade represents a 8.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the sale, the executive vice president owned 42,186 shares in the company, valued at $3,950,718.90. This represents a 3.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 61,903 shares of company stock valued at $5,889,203 in the last quarter. Insiders own 0.27% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on MDT. Robert W. Baird increased their target price on shares of Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 2nd. Wells Fargo & Company lifted their price target on shares of Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research report on Wednesday, September 2nd. Weiss Ratings upgraded shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 19th. Truist Financial reiterated a “hold” rating and issued a $99.00 price target (up from $86.00) on shares of Medtronic in a research note on Wednesday, September 2nd. Finally, UBS Group reissued a “cautious” rating on shares of Medtronic in a research report on Wednesday, October 14th. Eighteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $103.75.
Read Our Latest Analysis on Medtronic
Trending Headlines about Medtronic
Investors following MDT have been watching these headlines:
- Positive Sentiment: The FDA cleared Medtronic’s Hugo robotic-assisted surgery system for general surgery, expanding its potential U.S. market to procedures representing roughly 3.5 million cases annually. Broader access could support adoption and future sales. Medtronic’s Hugo robot gets expanded FDA clearance in general surgery
- Positive Sentiment: Analyst coverage points to Hugo adoption, international expansion and Neuroscience advances as potential growth drivers. A separate Q2 preview also cited cardiovascular performance, including cardiac ablation, as a possible source of momentum. Should You Continue to Hold Medtronic Stock in Your Portfolio?
- Neutral Sentiment: A market recap said MDT declined more than the broader market, but offered no company-specific explanation for the move. Medtronic Declines More Than Market
Medtronic Company Profile
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
Featured Articles
- Five stocks we like better than Medtronic
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
